Crowdonomics
All companies

Zimmerman BioPharma Holding, Inc.

Operating

Biotech · Austin, TX

Estimated pre-money ⓘ
$126.0M
As of Mar 2020 · from Reg A Offering (2020) · our estimate: offering price × shares outstanding, not a stated valuation
Total raised
$0
Across 1 round since 2020
Latest share price
$0.18
Reg A Offering (2020) offering price

Financials

FY2018–FY2019 · from SEC filings · hover any figure for its source
$1.4M
−$8K
2018
$1.4M
−$8K
2019
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2018
FY2019
Income statement
Revenue
$1,415,640
$1,415,640
Cost of goods sold
$852,621
$852,621
Gross margin
40%
40%
Net income
-$7,959
-$7,959
Balance sheet
Cash
$0
$0
Accounts receivable
$0
$0
Total assets
$0
$0
Long-term debt
$0
$0
Total liabilities
$125,000
$125,000
Other
Headcount
2
2

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Pre-money — the valuation set before each round’s money came in
$126.0M
est. pre-money
Reg A+ · Equity · Mar 2020

Dotted grey bars are our estimate for rounds that didn't state one: the round's share price × the shares outstanding in its filings. Same measure as blue, but rougher.

Cap table

Share counts as of Jul 10, 2020
Series A-1 Preferred Stock · 0.43%Common Stock · 99.6%
ClassOutstandingVotes / shareShare of totalLast price
Series A-1 Preferred Stockpreferred3,000,000—0.43%—
Common Stock699,991,000199.6%—
Total702,991,000100%

From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.

Fundraising history

Raised $0 / $12.6MEst. pre-money $126M

Team

3 people
David J. Wood
Director and Chief Executive Officer
Ronald E. Zimmerman
Director and Chief Scientific Officer
Jackson L. Morris
Corporation Secretary

Names and titles as disclosed on SEC Form 1-A. Bios and photos come from the platform campaign page and may be out of date.

SEC filings

  • Form 1-A-WNov 6, 20200001575705-20-000234
    EDGAR
  • Form 1-A/AJul 10, 20200001575705-20-000128
    EDGAR
  • Form 1-A/AJun 5, 20200001575705-20-000100
    EDGAR
  • Form 1-AMar 5, 20200001575705-20-000019
    EDGAR
Source: SEC EDGARCIK 0001797807FLShare price $0.18Last synced Aug 16, 2026

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.